Director/PDMR Share Dealings
January 8, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
it has been notified that Dr. Steven Gillis, Non-Executive Director of the
Company, was recently informed that American Depositary Shares ("ADSs"), as set
out below, were acquired on his account by an independent third party
exercising discretion over dealing decisions. The transactions took place on
the NASDAQ.
Date of Number of ADSs Average price per ADS
transaction acquired
October 30, 2014 127 $196.744
December 19, 2014 76 $218.16
Following the above transactions, Dr. Gillis holds 674 ADSs. One ADS is equal
to three ordinary shares of 5 pence each in the Company.
This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules ("DTRs"). In accordance with 3.1.5(R)
of the DTRs, the information required to be included in this notification was
received by the Company today, January 8, 2015.
For further information please contact:
Investor Relations
Jeff Poulton jpoulton@shire.com +1 781 482 0945
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com